Clinical trials: Chronic Psychosis
Smoking Behavior in Schizophrenia
Quetiapine Decreases Smoking in Patients With Chronic Schizophrenia
A single-blind switching study in which forty subjects currently being treated with risperidone will be randomly assigned to either stay on risperidone or switched to quetiapine.
- Trial name
- NCT00231101
- Testing
- Quetiapine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Arthur P. Noyes Research Foundation
Post Acute COVID-19 Syndrome
Cognitive-behavioral Therapy for Mental Disorder in COVID-19 Survivors
The consequences of the Intensive Care Unit and the Covid-19 disease are still uncertain. However, many studies are bringing out often psychological and dramatic consequences for many COVID-survivor patients.
- Trial name
- LONGCOVID (NCT05815693)
- Testing
- mindfulness-based stress reduction (MBSR) and cognitive behavioral therapy (CBT)
- Where
- Italy
- Volunteers
- 140 people
- Sponsor
- Azienda Socio Sanitaria Territoriale di Lecco
Chronic Disease, Mental Disorder
Reducing Cardiovascular Risk in Adults With Serious Mental Illness
This purpose of this study is to adapt, implement and test the ability of a sophisticated point-of-care electronic health record-based clinical decision support that identifies and prioritizes all available evidence-based…
- Conditions
- Chronic Disease, Mental Disorder, Health Behavior, Bipolar Disorder
- Trial name
- SMIWizard (NCT02451670)
- Testing
- Prioritized Clinical Decision Support
- Where
- 3 sites in United States
- Volunteers
- 10,347 people
- Sponsor
- HealthPartners Institute
Chronic Schizophrenia
Cognitive Remediation and Sheltered Employment in Schizophrenia
This study, driven on schizophrenic patients, is aimed at : 1. Measuring the efficiency of the cognitive remediation program RECOS (COgnitive REmediation in Schizophrenia) on the capacity of the patients suffering from…
- Trial name
- RemedRehab (NCT01891929)
- Testing
- RECOS (COgnitive REmediation for Schizophrenia), TAU (Treatment As Usual)
- Where
- 13 sites in France
- Volunteers
- 79 people
- Sponsor
- Hôpital le Vinatier
Physical Disability, Chronic Mental Disorder
Persons With Disabilities Generating Quality Metrics
No standard way exists to measure the quality of medical care or independent living long-term services and supports provided to persons with disabilities.
- Trial name
- NCT02390557
- Testing
- Survey, YESHealth
- Volunteers
- 451 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia
The purpose of the study is to investigate whether blockade of the histamine H2 receptors in the brain will have any beneficial effect on the symptoms of subjects with schizophrenia.
- Trial name
- NCT00565175
- Testing
- famotidine
- Where
- 5 sites in Finland
- Volunteers
- 30 people
- Sponsor
- Jesper Ekelund
Schizophrenias, Psychoses
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia
Adjuvant N-methyl-D-aspartic acid (NMDA)-enhancing agents, such as GlyT-1 inhibitors and NMDA-glycine site agonists have been demonstrated to be beneficial for chronic schizophrenia patients.
- Conditions
- Schizophrenias, Psychoses, Psychotic Disorders, Schizophrenic Disorders
- Trial name
- NCT00960219
- Testing
- D-amino acid oxidase inhibition (DAAOI-1)
- Where
- Taiwan
- Volunteers
- 52 people
- Sponsor
- China Medical University Hospital
Transcranial Direct Current Stimulation, Smoking, Cigarette
tDCS and Cognitive Training Intervention for Chronic Smokers With Schizophrenia
This study is being done to develop new methods to help smokers with schizophrenia to successfully reduce their smoking and/or quit. This is not a treatment study, but will help find new techniques to create better treatments.
- Conditions
- Transcranial Direct Current Stimulation, Smoking, Cigarette, Schizophrenia
- Trial name
- TACTICSS (NCT03588728)
- Testing
- Transcranial Direct Current Stimulation, Cognitive Remediation (CR)
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Pittsburgh
Schizophrenia, Schizoaffective Disorder
Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.
A Multicenter, Double-blind 16 Week Study on the augmentation of atypical antipsychotic with Aripiprazole in patients with Schizophrenia with inadequate response to antipsychotic treatment.
- Trial name
- NCT00325689
- Testing
- Quetiapine or Risperidone + Aripiprazole
- Where
- 48 sites in United States
- Volunteers
- 323 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Understanding How Cognitive Remediation Works
This study is aimed at evaluating whether the computer-based cognitive exercises in the Thinking Skills for Work (TSW) program are critical to improving work and cognitive outcomes in consumers with serious mental illness and…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Chronic Mental Disorder, Major Depression
- Trial name
- Cog-2 (NCT01683539)
- Testing
- The Thinking Skills for Work Program, The Cognitive Skills for Work Program
- Where
- 2 sites in United States
- Volunteers
- 203 people
- Sponsor
- Boston University Charles River Campus
Gambling
Effectiveness of Exergames on Cognitive, Social Functionamong Chronic Schizophrenia
An experimental study with random assignment will be adopted. The participants from 2 hospitals will be assigned to two groups: experimental group (n=77), and control group (n=77).
- Trial name
- exergames (NCT05933356)
- Testing
- playing exergames, scheduled activities
- Where
- Taiwan
- Volunteers
- 154 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Ischemia, Cardiac Insufficiency
Detection and Treatment of Somatic Disease in Patients With Severe Mental Disease
In Denmark, around 2 % of the population live with severe mental disease. People with severe mental disease live 15-20 years less than the general population.
- Conditions
- Ischemia, Cardiac Insufficiency, Diabetes Mellitus, Type 2, Hypertension
- Trial name
- NCT03428308
- Testing
- Screening, Treatment
- Volunteers
- 90 people
- Sponsor
- Intersectoral Research Unit for Health Services
Schizophrenia
A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia
This is a Phase 1, open-label study to evaluate the safety and pharmacokinetics (PK) of three doses of risperidone-SABER, administered with a needle and syringe or via the DosePro Needle-Free Delivery System in patients with…
- Trial name
- NCT01592110
- Testing
- risperidone-SABER, ZX003:risperidone-SABER and the DosePro System
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Zogenix, Inc.